Sponsored

Imugene (ASX: IMU) shares up on Chinese patent for oncolytic virotherapy CF33 - Kalkine Media

April 04, 2024 12:16 PM AEDT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • A Notice of Grant received from the Chinese Patent Office for IMU’s oncolytic virotherapy CF33.
  • Previously, grants were obtained in South Korea and Japan.
  • The patents extend protection for the method of composition and method of use until 2037.
  • China is the largest pharmaceutical market in the Asian region.

Shares of Imugene Limited (ASX: IMU) jumped by over 7% during the early morning trading session on 4 April 2024, following an exciting company update regarding its oncolytic virotherapy CF33.

The company has secured a patent in China for its oncolytic virotherapy CF33. This adds to previous grants obtained in Japan and South Korea, underscoring the global recognition of Imugene's innovative oncolytic virotherapy, CF33.

The grant protects CF33 which covers VAXINIA (CF33-hNIS) and CHECKvacc (CF33-hNIS-antiPDL1).

Details of the patent granted in China:

The title of the patent is –

The patent extends protection to the method of use and composition of IMU’s licensed oncolytic virotherapy to 2037.

At the helm of this groundbreaking technology is Professor Yuman Fong, whose expertise in oncolytic viruses has been pivotal.  

CF33, a chimeric vaccinia poxvirus developed in his laboratory, is designed to selectively target and eliminate tumor cells while stimulating the body's immune response against cancer.

IMU shares traded at AU$0.112 apiece at the time of writing on 4 April 2024.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



Top ASX Listed Companies


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.